Most Read Articles
5 days ago
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 
29 Jan 2019
Carfilzomib in combination with dexamethasone (Kd) is effective and safe in patients with multiple myeloma (MM) relapsing on or after lenalidomide and those with lenalidomide-refractory disease, a combined analysis of carfilzomib trials has shown.
29 Jan 2019
A curative strategy for smoldering multiple myeloma (SMM) that involves induction therapy with carfilzomib, lenalidomide and dexamethasone (KRd) followed by high-dose melphalan and autologous stem cell transplantation (ASCT), KRd consolidation, and maintenance with lenalidomide and dexamethasone has demonstrated promising results in a phase II trial.
Pearl Toh, 07 Mar 2019
Sacituzumab govitecan, a novel investigational antibody-drug conjugate, showed clinical activity in patients with metastatic urothelial carcinoma (mUC) who had progressed following standard therapy, including treatment with checkpoint inhibitors, according to an early study presented at GUCS 2019.

Physical activity protects against colon cancer risk

14 Apr 2018

Higher levels of physical activity appear to reduce the risk of developing colon cancer, independent of colonic subsite, according to a study. Conversely, sedentary behaviour is associated with an increased risk.

The study population comprised 430,584 men and women from the UK Biobank. Multivariable Cox proportional hazards models were used to analyse physical activity levels (metabolic equivalents (METs)-hours per week) and sedentary behaviour indicators (television watching time and time spent using computers) in relation to the risk of colorectal cancer.

A total of 2,391 patients developed colon cancer during a median follow-up of 5.6 years. On analysis, higher levels of total physical activity (60-MET-hours per week) showed a protective effect on the risk of colon cancer (vs <10-MET-hours per week: hazard ratio, 0.84; 95 percent CI, 0.72–0.98; p=0.04 for trend), with comparable relationships observed for proximal and distal colon tumours.

Physical activity was not associated with rectal cancer.

With respect to sedentary behaviour, higher levels of television watching time showed a positive association with colon cancer risk. Compared with 1 hour/day of television watching time, 5 hours/day increased the risk of developing colon cancer by 1.32 times (1.04–1.68; p=0.007 for trend). This relationship was not observed for rectal cancer.

Neither colon nor rectal cancer was associated with time spent using computers.

Findings of the present study contribute to the large body of evidence supporting the promotion of physical activity in population-wide cancer prevention programmes, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 
29 Jan 2019
Carfilzomib in combination with dexamethasone (Kd) is effective and safe in patients with multiple myeloma (MM) relapsing on or after lenalidomide and those with lenalidomide-refractory disease, a combined analysis of carfilzomib trials has shown.
29 Jan 2019
A curative strategy for smoldering multiple myeloma (SMM) that involves induction therapy with carfilzomib, lenalidomide and dexamethasone (KRd) followed by high-dose melphalan and autologous stem cell transplantation (ASCT), KRd consolidation, and maintenance with lenalidomide and dexamethasone has demonstrated promising results in a phase II trial.
Pearl Toh, 07 Mar 2019
Sacituzumab govitecan, a novel investigational antibody-drug conjugate, showed clinical activity in patients with metastatic urothelial carcinoma (mUC) who had progressed following standard therapy, including treatment with checkpoint inhibitors, according to an early study presented at GUCS 2019.